MX395336B - Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. - Google Patents
Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.Info
- Publication number
- MX395336B MX395336B MX2018003306A MX2018003306A MX395336B MX 395336 B MX395336 B MX 395336B MX 2018003306 A MX2018003306 A MX 2018003306A MX 2018003306 A MX2018003306 A MX 2018003306A MX 395336 B MX395336 B MX 395336B
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- pharmaceutical preparation
- application
- medicine
- stable anti
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Una preparación farmacéutica del anticuerpo anti-PD-1 estable y una aplicación de la misma en un medicamento. La preparación farmacéutica del anticuerpo anti-PD-1 comprende un anticuerpo anti-PD-1, un amortiguador y puede comprender además al menos un tipo de estabilizante, y opcionalmente puede comprender además un tensoactivo. La preparación farmacéutica del anticuerpo anti-PD-1 de la presente invención puede suprimir eficazmente la agregación y desaminación de anticuerpos, evitando de este modo la degradación de un producto de anticuerpo, obteniendo una preparación farmacéutica inyectada estable.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510629020 | 2015-09-28 | ||
| PCT/CN2016/098982 WO2017054646A1 (zh) | 2015-09-28 | 2016-09-14 | 一种抗pd-1抗体制剂及其在医药上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018003306A MX2018003306A (es) | 2018-05-16 |
| MX395336B true MX395336B (es) | 2025-03-25 |
Family
ID=58422670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003306A MX395336B (es) | 2015-09-28 | 2016-09-14 | Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10786567B2 (es) |
| EP (1) | EP3357508A4 (es) |
| JP (1) | JP6921062B2 (es) |
| KR (1) | KR20180054791A (es) |
| CN (1) | CN106999591B (es) |
| AU (1) | AU2016329960A1 (es) |
| BR (1) | BR112018005349A2 (es) |
| CA (1) | CA2999079A1 (es) |
| MX (1) | MX395336B (es) |
| RU (1) | RU2731418C2 (es) |
| TW (1) | TWI721020B (es) |
| UA (1) | UA124259C2 (es) |
| WO (1) | WO2017054646A1 (es) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗pd−1抗体及びその使用方法 |
| EP3357508A4 (en) | 2015-09-28 | 2019-04-24 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE |
| BR112018006237A2 (pt) | 2015-09-29 | 2018-10-09 | Celgene Corp | proteínas de ligação a pd-1 e métodos de uso das mesmas |
| PT3370768T (pt) | 2015-11-03 | 2022-04-21 | Janssen Biotech Inc | Anticorpos que se ligam especificamente ao pd-1 e seus usos |
| EP3515944A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHOD FOR TREATING IMMUNE DISEASES USING PD-1 BINDING PROTEINS |
| EP3515943A4 (en) | 2016-09-19 | 2020-05-06 | Celgene Corporation | METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| RU2766590C2 (ru) | 2017-05-16 | 2022-03-15 | Цзянсу Хэнжуй Медисин Ко., Лтд. | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |
| US11273205B2 (en) * | 2017-07-25 | 2022-03-15 | Jiangsu Hengrui Medicine Co., Ltd. | IL-15 protein complex pharmaceutical composition |
| CN111132696B (zh) * | 2017-10-13 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 |
| CN111094339B (zh) * | 2017-10-17 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 |
| EP3705134A4 (en) * | 2017-11-02 | 2021-07-28 | Nanjing Shunxin Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1 |
| CN109793892B (zh) * | 2017-11-16 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体在制备治疗食管癌的药物中的用途 |
| WO2019096194A1 (zh) * | 2017-11-16 | 2019-05-23 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 |
| CN109893654B (zh) * | 2017-12-11 | 2021-07-27 | 江苏恒瑞医药股份有限公司 | Vegfr抑制剂治疗肿瘤的方法 |
| CN111246881B (zh) * | 2017-12-14 | 2023-03-10 | 江苏恒瑞医药股份有限公司 | Pd-1抗体用于治疗肿瘤的用途 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| CN110272491B (zh) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体的纯化工艺 |
| CN110404066B (zh) * | 2018-04-28 | 2022-06-17 | 齐鲁制药有限公司 | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 |
| CN110448691A (zh) * | 2018-05-07 | 2019-11-15 | 江苏恒瑞医药股份有限公司 | 抗pd-1抗体联合il-15蛋白复合物在制备治疗肿瘤的药物中的用途 |
| KR20210030366A (ko) | 2018-06-20 | 2021-03-17 | 인사이트 코포레이션 | 항-pd-1 항체 및 이의 용도 |
| AU2019323435A1 (en) * | 2018-08-20 | 2021-02-18 | Jiangsu Hengrui Medicine Co., Ltd. | Use of TIM-3 antibody in preparation of medicines for treating tumors |
| MX2021004356A (es) | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
| MA54089A (fr) | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| JP7883848B2 (ja) * | 2018-11-06 | 2026-07-02 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | 腫瘍を治療するための薬物の調製におけるファミチニブと組み合わせた抗pd-1抗体の使用 |
| US20210380694A1 (en) * | 2018-11-07 | 2021-12-09 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| JP7503056B6 (ja) * | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗lag3抗体および抗pd-1抗体の共-製剤 |
| CN111346225A (zh) * | 2018-12-21 | 2020-06-30 | 上海张江生物技术有限公司 | 含有蛋白质的药物制剂 |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| US20220241412A1 (en) | 2019-05-24 | 2022-08-04 | Pfizer Inc. | Combination therapies using cdk inhibitors |
| EP4077388A1 (en) * | 2019-12-18 | 2022-10-26 | Tesaro, Inc. | Biopharmaceutical compositions and related methods |
| US20230355757A1 (en) | 2019-12-20 | 2023-11-09 | Formycon Ag | Formulations of anti-pd1 antibodies |
| TW202130367A (zh) * | 2020-01-15 | 2021-08-16 | 大陸商信達生物製藥(蘇州)有限公司 | 結合pd-1和pd-l1的雙特異性抗體的製劑及其用途 |
| KR20210097882A (ko) * | 2020-01-30 | 2021-08-10 | 삼성바이오에피스 주식회사 | 안정한 항-pd-1 항체 약제학적 제제 |
| CN115279405B (zh) * | 2020-04-10 | 2025-02-18 | 江苏恒瑞医药股份有限公司 | 一种抗pd-1抗体在制备治疗肢端黑色素瘤的药物中的用途 |
| EP4137155A4 (en) * | 2020-04-17 | 2024-10-30 | Shihuida Pharmaceutical Group (Jilin) Co., Ltd. | PREPARATION SPECIFICALLY RELATED TO CD137 AND ITS USE |
| US20230295329A1 (en) * | 2020-07-31 | 2023-09-21 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-pd-1 antibody pharmaceutical composition and use thereof |
| CN114099423A (zh) * | 2020-08-25 | 2022-03-01 | 泰州迈博太科药业有限公司 | 一种靶向cd47与pd-l1双功能融合蛋白的制剂 |
| US20230365692A1 (en) | 2020-09-24 | 2023-11-16 | Merck Sharp & Dohme Llc | Stable formulations of programmed death receptor 1 (pd-1) antibodies and hyaluronidase variants and fragments thereof and methods of use thereof |
| CN114392352A (zh) * | 2020-09-27 | 2022-04-26 | 广东东阳光药业有限公司 | 一种稳定的抗pd-1抗体的药物制剂 |
| US20220168293A1 (en) | 2020-12-02 | 2022-06-02 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
| CN115212209B (zh) * | 2021-04-19 | 2023-11-28 | 中国科学院分子细胞科学卓越创新中心 | 一种具有免疫佐剂活性和促进免疫疗法的抗肿瘤药物 |
| WO2022223028A1 (zh) * | 2021-04-23 | 2022-10-27 | 上海君实生物医药科技股份有限公司 | 抗BLyS抗体、其药物组合物及其用途 |
| US20240287185A1 (en) | 2021-06-23 | 2024-08-29 | Formycon Ag | Formulations of anti-pd1 antibodies |
| US20240366757A1 (en) * | 2021-09-07 | 2024-11-07 | Dr. Reddy’S Laboratories Limited | Formulations of immune check point inhibitors or like |
| EP4398931A4 (en) * | 2021-09-07 | 2025-07-16 | Dr Reddys Laboratories Ltd | IMMUNE CHECKPOINT INHIBITOR FORMULATIONS |
| TW202327595A (zh) | 2021-10-05 | 2023-07-16 | 美商輝瑞大藥廠 | 用於治療癌症之氮雜內醯胺化合物的組合 |
| WO2023079428A1 (en) | 2021-11-03 | 2023-05-11 | Pfizer Inc. | Combination therapies using tlr7/8 agonist |
| WO2024023843A1 (en) * | 2022-07-26 | 2024-02-01 | Dr. Reddy’S Laboratories Limited | A pharmaceutical formulation of a therapeuticantibody and preparations thereof |
| CN115656496A (zh) * | 2022-10-28 | 2023-01-31 | 迪瑞医疗科技股份有限公司 | 一种普适型冻干保护剂及其应用 |
| US20260207493A1 (en) | 2022-12-21 | 2026-07-23 | Formycon Ag | Formulations of anti-pd1 antibodies |
| WO2024171082A1 (en) | 2023-02-16 | 2024-08-22 | Sun Pharmaceutical Industries Limited | Stable protein compositions of anti-pd1 antibody |
| WO2026133192A1 (en) | 2024-12-20 | 2026-06-25 | Pfizer Inc. | Combination therapies using cdk4 inhibitors with pd-1 axis binding antagonists |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1034292A (zh) * | 1988-01-15 | 1989-07-26 | 翁文聘 | 异步整流发电机 |
| JPH03504605A (ja) * | 1988-05-27 | 1991-10-09 | セントカー・インコーポレーテツド | 抗体産生物の凍結乾燥した配合物 |
| GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| EP3530736A3 (en) * | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| JP2009525986A (ja) * | 2006-02-03 | 2009-07-16 | メディミューン,エルエルシー | タンパク質製剤 |
| CA2647111A1 (en) * | 2006-03-28 | 2007-10-04 | F. Hoffmann-La Roche Ag | Anti-igf-1r human monoclonal antibody formulation |
| JP2010531340A (ja) * | 2007-07-10 | 2010-09-24 | エフ.ホフマン−ラ ロシュ アーゲー | 新規処方物 |
| US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| US20110158987A1 (en) * | 2009-12-29 | 2011-06-30 | F. Hoffmann-Laroche Ag | Novel antibody formulation |
| CN102892786B (zh) * | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| TW201134488A (en) * | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| WO2012135408A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| US10513555B2 (en) * | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| CR20160319A (es) * | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| US10899840B2 (en) * | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| EP3357508A4 (en) | 2015-09-28 | 2019-04-24 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | STABLE PHARMACEUTICAL ANTI-PD-1 ANTIBODY PREPARATION AND APPLICATION THEREOF IN MEDICINE |
-
2016
- 2016-09-14 EP EP16850270.6A patent/EP3357508A4/en not_active Withdrawn
- 2016-09-14 UA UAA201804310A patent/UA124259C2/uk unknown
- 2016-09-14 JP JP2018515764A patent/JP6921062B2/ja not_active Expired - Fee Related
- 2016-09-14 US US15/761,552 patent/US10786567B2/en active Active
- 2016-09-14 BR BR112018005349-0A patent/BR112018005349A2/pt not_active IP Right Cessation
- 2016-09-14 MX MX2018003306A patent/MX395336B/es unknown
- 2016-09-14 RU RU2018110333A patent/RU2731418C2/ru active
- 2016-09-14 WO PCT/CN2016/098982 patent/WO2017054646A1/zh not_active Ceased
- 2016-09-14 AU AU2016329960A patent/AU2016329960A1/en not_active Abandoned
- 2016-09-14 KR KR1020187011041A patent/KR20180054791A/ko not_active Withdrawn
- 2016-09-14 CA CA2999079A patent/CA2999079A1/en not_active Abandoned
- 2016-09-14 CN CN201680003949.4A patent/CN106999591B/zh active Active
- 2016-09-29 TW TW105131263A patent/TWI721020B/zh active
-
2020
- 2020-09-02 US US16/948,077 patent/US20210000954A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| UA124259C2 (uk) | 2021-08-18 |
| JP2018532730A (ja) | 2018-11-08 |
| JP6921062B2 (ja) | 2021-08-18 |
| TW201711699A (zh) | 2017-04-01 |
| AU2016329960A1 (en) | 2018-04-26 |
| BR112018005349A2 (pt) | 2018-10-09 |
| TWI721020B (zh) | 2021-03-11 |
| KR20180054791A (ko) | 2018-05-24 |
| EP3357508A1 (en) | 2018-08-08 |
| CN106999591A (zh) | 2017-08-01 |
| MX2018003306A (es) | 2018-05-16 |
| US20180339045A1 (en) | 2018-11-29 |
| US20210000954A1 (en) | 2021-01-07 |
| CA2999079A1 (en) | 2017-04-06 |
| RU2731418C2 (ru) | 2020-09-02 |
| WO2017054646A1 (zh) | 2017-04-06 |
| RU2018110333A (ru) | 2019-10-28 |
| US10786567B2 (en) | 2020-09-29 |
| EP3357508A4 (en) | 2019-04-24 |
| CN106999591B (zh) | 2021-02-23 |
| RU2018110333A3 (es) | 2019-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018003306A (es) | Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. | |
| ZA202303593B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| DOP2018000074A (es) | Moduladores de la proteína core de la hepatitis b | |
| CL2016002269A1 (es) | Moduladores alostéricos del núcleo proteico de la hepatitis b. | |
| EP3402548C0 (en) | OCCLUSION RESOLUTION IN DRUG DELIVERY DEVICES, SYSTEMS, AND METHODS | |
| DOP2018000297A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| MX2017006653A (es) | Metodos para modular los niveles de fármaco en plasma mediante el uso de eritrohidroxibupropión. | |
| GEP20217243B (en) | Orodispersible dosage unit containing an estetrol component | |
| SG10201902407PA (en) | Injectable microparticles for hyper-localized release of therapeutic agents | |
| PH12017501084A1 (en) | Insulin glargine/lixisenatide fixed ratio formulation | |
| EP3318282A4 (en) | AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| TW201613557A (en) | Stable aqueous recombinant protein formulations | |
| ES3063790T3 (en) | Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules | |
| MX2022006770A (es) | Dispersiones solidas de bendamustina e infusion continua. | |
| WO2015031598A3 (en) | Therapeutic dnp derivatives and methods using same | |
| WO2017079403A3 (en) | Polymeric nanoparticles | |
| MX2016015261A (es) | Dispersion solida de allisartan isoproxilo y su composicion. | |
| MX2019014666A (es) | Composicion farmaceutica que comprende un conjugado de anticuerpo contra c-met-farmaco y uso del mismo. | |
| EP3313390A4 (en) | INTRAVENOUS ADMINISTRATION OF CITRULLIN DURING SURGICAL PROCEDURE | |
| MX2017013795A (es) | Combinaciones terapeuticas de tratamientos antivirales y antiinflamatorios. | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| GT201600158A (es) | Filtros para equipos de infusión | |
| BR112017014295A2 (pt) | composição farmacêutica. | |
| AR108280A1 (es) | Composición oftálmica que comprende una combinación sinérgica de glucógeno y ácido hialurónico o sal del mismo |